Cancer-Targeting Compound 1

Telomerase Inhibition and Telomere Targeting in Hematopoietic Cancer Cell Lines with Small Non-Nucleosidic Synthetic Compounds (BIBR1532)

BIBR1532 that is a selective, non-nucleosidic inhibitor of the catalytic component hTERT. Treatment of cancer cells with this compound leads to progressive telomere shortening, consecutive telomere dysfunction, and finally growth arrest after a lag

Development of a Cell-Based Assay to Quantify the Inflammatory Potential of Test Substances and Screen Compound Libraries for Anti-cancer Drug Candida

stimulation. In addition, application of cell based assays simultaneously permits entry level evaluation of compound toxicity and endows with a powerful approach to perform high-throughput screenings of, e.g., small molecule libraries in a quest for novel

An Engineered Peptide Compound Platform Technology Incorporating Angiopep for Crossing the BBB

family is the base of the engineered peptide compound (EPiC) platform technology allowing the synthesis of compounds which enter the central nervous system (CNS) to treat brain disorders. Using the EPiC platform, active drugs are modified by incorporation